| Autor: |
Downey DG; Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK. Electronic address: d.downey@qub.ac.uk., Simmonds NJ; Adult Cystic Fibrosis Centre, Royal Brompton Hospital, part of Guy's and St Thomas' NHS Foundation Trust, London, UK; National Heart and Lung Institute, Imperial College London, London, UK., van-Koningsbruggen-Rietschel S; CF Centre, Pediatric Pulmonology and Allergology, University Children's Hospital Cologne, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany; Centre for Rare Diseases, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937, Cologne, Germany., Bend J; Mukoviszidose e.V. & Mukoviszidose Institut gGmbH In den Dauen 6, 53117, Bonn, Germany., Dunlevy F; European Cystic Fibrosis Society Clinical Trials Network, Karup, Denmark., Hill K; European Cystic Fibrosis Society Clinical Trials Network, Karup, Denmark; Northern Ireland Clinical Research Facility, Wellcome-Wolfson Institute for Experimental Medicine, Queen's University Belfast, Belfast, UK., Dupont L; University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. |
| Abstrakt: |
Competing Interests: Declaration of competing interest KH and FD report funding by ECFS for travel to attend international conferences/meetings. DGD reports grants or contracts from Chiesi, Gilead, CF Trust; consulting fees from Chiesi, Insmed, Vertex; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events from Vertex; funding by ECFS, CFF and CF Trust for travel to attend international conferences/meetings; participation in a DSMB for NOMAB trial; previous Director of ECFS CTN (2021–2023). SvKR reports consulting fees for BiomX Inc and PureIMS; payment or honoraria for lectures, presentations, speaker bureaus, manuscript writing or educational events for Vitalograph; ECFS Vice-President and Steering Committee Member for ECFS. LD is the current Director of the ECFS CTN. JB has no conflict of interest to declare. NJS reports grants or contracts from CF Trust Development Award, Vertex Innovation Award, Royal-Brompton-Kings Health Partnership Clinical Transformation Award; consulting fees for Vertex, Gilead, Chiesi and Menarini; educational lectures for Vertex, Gilead and Chiesi; travel support from Chiesi, Vertex and Pari and participation on DSMB for academic study for Papworth/Cambridge University. Deputy Director of the ECFS Clinical Trials Network, Chair of ECFS Protocol Review Committee, Co-Coordinator of ECFS Diagnostic Network Working Group, Chair of UK CF Registry Research Committee, UK CF Trust Research Strategy Oversight Board Committee and Lead |
Full Text from ScienceDirect